| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| XOMA Corp | CEO, Director | 8.625% Series A Cumulative Perpetual Preferred Stock | 8,000 | $204,800 | $25.60 | 15 Jul 2022 | By spouse |
| XOMA Corp | CEO, Director | Depositary Shares - 8.375% B Cumulative Stock | 8,000 | $190,320 | $23.79 | 15 Jul 2022 | By spouse |
| XOMA Corp | CEO, Director | Common Stock | 11,822 | $164,208 | $13.89 | 15 Jul 2022 | Direct |
| XOMA Corp | CEO, Director | Common Stock | 5,560 | $77,228 | $13.89 | 15 Jul 2022 | By 401(k) Plan |
| Akari Therapeutics Plc | Director | American Depositary Shares representing Ordinary Shares | 36,271 | $40,624 | $1.12 | 20 Mar 2025 | Direct |
| Akari Therapeutics Plc | Director | Ordinary Shares, par value $0.0001 per share | 32,216,000 | $19,330 | $0.000600 | 09 Jan 2025 | Direct |
| Akari Therapeutics Plc | Director | Series A Warrants (Right to Buy) | 4,464 | $5,000 | $1.12 | 06 Mar 2025 | Direct |
| Akari Therapeutics Plc | Director | Series B Warrants (Right to Buy) | 4,464 | $5,000 | $1.12 | 06 Mar 2025 | Direct |
| PALISADE BIO, INC. | Director | Common Stock, par value $0.01 | 10,920 | $4,762 | $0.4361 | 09 Feb 2024 | Direct |
| PALISADE BIO, INC. | Director | Restricted Stock Units | 0 | $0 | $0.4361 | 09 Feb 2024 | Direct |
| Peak Bio, Inc. | Director | Common Stock | 0 | $0 | $0.2650 | 14 Nov 2024 | Direct |
| Processa Pharmaceuticals, Inc. | Director | Stock Options (Right to Buy) | 300,000 | 01 Oct 2025 | Direct | ||
| Akari Therapeutics Plc | Director | Stock Option (Right to Buy) | 225,000 | 20 Mar 2025 | Direct | ||
| XOMA Corp | CEO, Director | Stock Option (Right to Buy) | 218,056 | 15 Jul 2022 | Direct | ||
| Processa Pharmaceuticals, Inc. | Director | Restricted Stock | 206,505 | 24 Jul 2025 | Direct | ||
| Processa Pharmaceuticals, Inc. | Director | Restricted Stock Units | 100,000 | 01 Oct 2025 | Direct | ||
| Monterey Bio Acquisition Corp | Director | Common Stock | 35,000 | 30 Sep 2021 | Direct | ||
| PALISADE BIO, INC. | Director | Common Stock Options | 6,880 | 09 Feb 2024 | Direct | ||
| Peak Bio, Inc. | Director | Convertible Notes | 0 | 14 Nov 2024 | Direct | ||
| Peak Bio, Inc. | Director | Stock Option (Right to Buy) | 0 | 14 Nov 2024 | Direct | ||
| Peak Bio, Inc. | Director | Warrant (Right to Purchase) | 0 | 14 Nov 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PCSA | Processa Pharmaceuticals, Inc. | 01 Oct 2025 | 2 | $0 | 4 | Director | 03 Oct 2025, 16:41 |
| PCSA | Processa Pharmaceuticals, Inc. | 24 Jul 2025 | 1 | $0 | 4/A | Director | 18 Sep 2025, 16:19 |
| AKTX | Akari Therapeutics Plc | 20 Mar 2025 | 2 | $0 | 4 | Director | 24 Mar 2025, 17:00 |
| AKTX | Akari Therapeutics Plc | 06 Mar 2025 | 3 | +$14,999 | 4 | Director | 10 Mar 2025, 17:00 |
| AKTX | Akari Therapeutics Plc | 09 Jan 2025 | 1 | +$4,800 | 4 | Director | 10 Jan 2025, 17:30 |
| AKTX | Akari Therapeutics Plc | 23 Dec 2024 | 1 | +$1,000 | 4 | Director | 26 Dec 2024, 16:30 |
| AKTX | Akari Therapeutics Plc | 14 Nov 2024 | 0 | $0 | 3 | Director | 22 Nov 2024, 16:30 |
| /report/000095017024128150-neal-james-r-2024-11-14 | Peak Bio, Inc. | 14 Nov 2024 | 5 | -$20,004 | 4 | Director | 18 Nov 2024, 18:54 |
| PCSA | Processa Pharmaceuticals, Inc. | 03 Sep 2024 | 1 | $0 | 4 | Director | 18 Sep 2024, 16:48 |
| PALI | PALISADE BIO, INC. | 09 Feb 2024 | 8 | $0 | 4 | Director | 13 Feb 2024, 15:08 |
| PALI | PALISADE BIO, INC. | 21 Nov 2023 | 2 | $0 | 4 | Director | 24 Nov 2023, 16:00 |
| PCSA | Processa Pharmaceuticals, Inc. | 27 Jun 2023 | 3 | $0 | 4 | Director | 24 Jul 2023, 18:38 |
| PALI | PALISADE BIO, INC. | 11 Jun 2023 | 2 | $0 | 4 | Director | 13 Jun 2023, 18:44 |
| /report/000089924323011993-neal-james-r-2023-04-28 | Peak Bio, Inc. | 28 Apr 2023 | 2 | +$20,004 | 4 | Director | 02 May 2023, 16:30 |
| /report/000089924322035071-neal-james-r-2022-11-01 | Peak Bio, Inc. | 01 Nov 2022 | 0 | $0 | 3 | Director | 03 Nov 2022, 21:47 |
| PCSA | Processa Pharmaceuticals, Inc. | 19 Jul 2022 | 1 | $0 | 4 | Director | 21 Jul 2022, 16:46 |
| PCSA | Processa Pharmaceuticals, Inc. | 19 Jul 2022 | 0 | $0 | 3 | Director | 21 Jul 2022, 16:44 |
| XOMA | XOMA Corp | 15 Jul 2022 | 5 | -$645,354 | 4 | CEO, Director | 18 Jul 2022, 16:30 |
| XOMA | XOMA Corp | 21 Mar 2022 | 9 | -$1,338,403 | 4 | CEO, Director | 23 Mar 2022, 18:52 |
| XOMA | XOMA Corp | 21 Dec 2021 | 1 | $0 | 4 | CEO, Director | 23 Dec 2021, 15:30 |
| PALI | PALISADE BIO, INC. | 18 Nov 2021 | 1 | $0 | 4 | Director | 10 Feb 2022, 17:19 |
| /report/000110465921121341-neal-james-r-2021-09-30 | Monterey Bio Acquisition Corp | 30 Sep 2021 | 0 | $0 | 3 | Director | 30 Sep 2021, 17:54 |
| XOMA | XOMA Corp | 25 Jun 2021 | 3 | -$303,474 | 4 | CEO, Director | 29 Jun 2021, 17:09 |